Skip to main content

Table 2 Average per-patient lifetime discounted costs and quality-adjusted life-years, by diagnostic outcome and strategy

From: Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease

 

Cost (U.S.$)

LYs

QALYs

Probability of each outcome

Lifetime discounted costs and benefits by diagnostic outcome

 AD

  True-positive

$298,632

6.781

2.916

8.9%

  False-negative

$308,586

6.555

2.660

3.8%

 Not AD

  False-positive

$294,732

9.157

5.048

5.2%

  True-negative

$283,387

9.157

5.048

82.1%

Lifetime discounted costs and benefits by diagnostic strategy

  Do nothing

$286,587 (244,438 to 337,270)

 

4.745 (3.88 to 5.42)

 

  Biomarker analysis (BM)

$286,752 (244,044 to 337,163)

 

4.760 (3.89 to 5.44)

 

  Incremental (BM vs. do nothing)

$165 (−1865 to 1625)

 

0.015 (−0.011 to 0.051)

 

Incremental cost-effectiveness ratio ($ per QALY gained)

$11,032a

 
  1. Abbreviations: AD Alzheimer’s disease, LY Life-year, QALY Quality-adjusted life-year
  2. aThe empiric distribution of incremental cost-effectiveness ratios (ICERs) over the 10,000 simulations identified a 40% probability that biomarker analysis (BM) will decrease costs and increase QALYs and a 7% probability that BM will increase costs and decrease QALYs, assuming an average AD prevalence of 12.7%. Therefore, the 95% CI over the ICER ranges from BM is cost-saving to BM is dominated. Empiric 95% CIs were estimated from 10,000 simulations in which all input parameters were varied simultaneously
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193